GAS5 and familial pancreatic carcinoma: lncRNA GAS5 was also found to enhance the therapeutic efficiency in various cancers, such as non-small cell lung cancer (NSCLC) [273], pancreatic cancer [274], and prostate cancer [275], thereby acting as a valuable tumoral suppressor.